Phase II multicenter study of low dose Cytarabine + Tosedostat for previously untreated older patients with acute myeloid leukemia (AML)
Phase of Trial: Phase II
Latest Information Update: 08 Dec 2015
Price : $35 *
At a glance
- Drugs Tosedostat (Primary) ; Cytarabine
- Indications Acute myeloid leukaemia
- Focus Therapeutic Use
- 08 Dec 2015 Results presented at the 57th Annual Meeting and Exposition of the American Society of Hematology
- 06 Dec 2015 According to the CTI BioPharma Corp., results were presented at 57th American Society of Hematology (ASH 2015).
- 06 Dec 2015 Results published in the CTI BioPharma Corp. media release.